mRNA vaccine responses in PLWH

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R21AI167705-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2024
  • Known Financial Commitments (USD)

    $204,688
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    ASSOCIATEPROFESSOR JOEL BLANKSON
  • Research Location

    United States of America
  • Lead Research Institution

    JOHNS HOPKINS UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

Project Summary Two mRNA COVID vaccines that have greater than 90% efficacy in healthy donors have been developed. However the efficacy of these vaccines in PLWH is unknown. PLWH have had suboptimal responses to some prior vaccines potentially because they make limited naïve T cell responses. We and others have shown T cell cross-recognition of spike proteins from SARS-CoV-2 and the common cold coronavirus and demonstrated that these cross-reactive responses are less effective against SARS-CoV-2 than mono- reactive responses. We hypothesize that cross-reactive memory responses will contribute more towards the total SARS-CoV-2 responses in PLWH than in healthy donors and this will result in less effective responses to the mRNA vaccines. We will test this hypothesis by comparing CD4+ T cell and antibody responses in vaccinated healthy donors and PLWH. Our results will have major implications for future policies regarding booster shots for PLWH and the general population